ARMLUPEG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARMLUPEG (ARMLUPEG).
Armlup peg is a recombinant human parathyroid hormone analog that acts as an anabolic agent on bone. It stimulates osteoblast activity, increasing bone formation and mass.
| Metabolism | Metabolized in the liver via nonspecific proteolytic degradation; further metabolism not fully characterized. |
| Excretion | Primarily renal (glomerular filtration) with 100% of the dose eliminated unchanged in urine. No appreciable biliary or fecal excretion. |
| Half-life | Terminal elimination half-life is 5-7 days intravenously. In patients with renal impairment (CrCl <30 mL/min), half-life extends to 10-12 days, necessitating dose adjustment. |
| Protein binding | Low protein binding: approximately 10-15%, primarily to albumin. |
| Volume of Distribution | Vd is approximately 0.05 L/kg, indicating minimal extravascular distribution and confinement to the plasma compartment. |
| Bioavailability | Only available as intravenous injection; bioavailability is 100% by this route. |
| Onset of Action | Intravenous: Onset of platelet count increase occurs within 2-3 weeks of initiating therapy. |
| Duration of Action | After cessation, platelet count returns to baseline over 2-4 weeks. Clinical effect duration is dependent on continued dosing. |
The typical adult dose is 0.5 mg/kg administered subcutaneously once every 2 weeks.
| Dosage form | INJECTION |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; insufficient data for GFR <30 mL/min or dialysis. |
| Liver impairment | No formal studies; no specific Child-Pugh based adjustments recommended. Use caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established; no weight-based dosing recommendations available for pediatric patients. |
| Geriatric use | No specific dose adjustment; dosing based on weight as in adults. Monitor renal function as clearance may decrease with age. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARMLUPEG (ARMLUPEG).
| Breastfeeding | No data available on ARMLUPEG excretion in human milk. Due to potential serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. M/P ratio unknown. |
| Teratogenic Risk | ARMLUPEG is an antineoplastic agent; based on its mechanism of action (inhibition of cell division), there is potential for teratogenicity. First trimester exposure carries highest risk of major congenital malformations. Second and third trimester exposure may cause fetal growth restriction and myelosuppression. Adequate human studies are lacking; animal studies have shown embryotoxicity and teratogenicity. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to armlup peg or any component","Paget's disease of bone","Unexplained elevations of alkaline phosphatase","Prior external beam or implant radiation therapy to the skeleton","Skeletal malignancies or bone metastases","Metabolic bone diseases other than osteoporosis","Pre-existing hypercalcemia"]
| Precautions | ["Risk of osteosarcoma (based on animal studies), limiting use to patients without other treatment options; avoid use in patients with Paget's disease, unexplained alkaline phosphatase elevations, skeletal malignancies, or prior radiation to the skeleton; hypercalcemia may occur; should not be used for longer than 2 years over a lifetime."] |
| Food/Dietary | No direct food interactions are known. However, patients with gout should avoid purine-rich foods (e.g., organ meats, shellfish) and alcohol to reduce uric acid levels. |
Loading safety data…
| Fetal Monitoring | Monitor complete blood count, hepatic function, and renal function regularly during pregnancy. Perform fetal ultrasound for growth and anatomy. Consider fetal monitoring for myelosuppression if used near term. |
| Fertility Effects | ARMLUPEG may impair fertility in both males and females based on animal studies. Reversible or irreversible infertility may occur. Preclinical data show potential for gonadal toxicity. |
| Clinical Pearls | ARMLUPEG (pegylated recombinant human urate oxidase) is used for refractory gout unresponsive to conventional therapy. Administer IV over at least 2 hours. Premedicate with antihistamines and corticosteroids to reduce infusion reactions. Screen for G6PD deficiency before use due to risk of hemolysis and methemoglobinemia. Monitor uric acid levels; goal is <6 mg/dL. Discontinue if severe hypersensitivity occurs. |
| Patient Advice | This medication is given as an intravenous infusion to lower high uric acid levels that other treatments have not controlled. · Before starting, you must be tested for G6PD deficiency. If you have this condition, you cannot receive this drug because it may cause red blood cell breakdown. · You will receive medications to prevent allergic reactions before each infusion. Report any symptoms like rash, itching, difficulty breathing, or chest pain during or after the infusion. · Due to risk of infusion reactions, you will be monitored closely during and after treatment. Infusions take at least 2 hours. · This drug may increase the risk of serious cardiovascular events. Seek immediate medical attention for chest pain, shortness of breath, or irregular heartbeat. · Do not take this medication if you are pregnant or breastfeeding unless approved by your doctor. |